Sage Therapeutics rejects Biogen's $469M buyout offer. CEO Barry Greene and board seek alternatives, with Goldman Sachs ...

Several drugmakers shared new clinical data at this year’s ASCO GI Symposium in San Francisco, and Endpoints News has rounded ...

Veru says its muscle-maintaining drug preserved more lean mass in older patients taking a GLP-1, but skittish investors ...

Metsera, a well-funded biotech trying to angle toward the front of the obesity medicine pack, has proposed a $250 million IPO ...

Investors typically celebrate IPOs as milestone moments — and potential exit opportunities — for their startups. In an ...

In a dramatic turnaround from bankruptcy court less than two years ago, Leerink Partners is now on the offensive and hiring ...

Akero Therapeutics claimed a win in severe MASH on Monday morning, as the company’s candidate efruxifermin showed a 24% ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

KEY TAKEAWAYS: 70% of Sponsors miss their milestones by an average of eight months, suggesting the clinical trial recruitment ...

Allakos reports Phase 1 failure, lays off 75% of staff: The biotech said AK006 did not produce a clinical benefit in patients ...

Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what ...